Persuading natural killer cells to eliminate bad B cells.
Clinical trials are underway infusing T cells genetically modified to be specific for B-cell malignancies using a chimeric antigen receptor (CAR) to redirect specificity for CD19. However, issues remain about whether the CAR can provide a fully competent application signal and whether other lymphocytes with lytic capacity can target CD19(+) tumors.
Cooper
Laurence J N
LJ
Division of Pediatrics, Children's Cancer Hospital, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA. ljncooper@mdanderson.org
D018941:Antigens, CD19 / Q000276:immunology* / Q000378:metabolism; D001402:B-Lymphocytes / Q000276:immunology* / Q000378:metabolism; D003602:Cytotoxicity, Immunologic; D006801:Humans; D007694:Killer Cells, Natural / Q000276:immunology* / Q000378:metabolism; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000276:immunology / Q000628:therapy; D015202:Protein Engineering; D011946:Receptors, Antigen / Q000235:genetics / Q000276:immunology*; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology* / Q000378:metabolism
D018941:Antigens, CD19; D011946:Receptors, Antigen; D011993:Recombinant Fusion Proteins